Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
about
Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.Evolution of bombesin conjugates for targeted PET imaging of tumors.Bombesin receptor-mediated imaging and cytotoxicity: review and current statusEffects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice.Tc-99m-labeled RGD-conjugated alpha-melanocyte stimulating hormone hybrid peptides with reduced renal uptakeDevelopment of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanomaEvaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting"Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.Radiopharmaceutical development of radiolabelled peptides.A high-affinity near-infrared fluorescent probe to target bombesin receptors.A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.
P2860
Q33725998-E9282D4A-ECAA-48E7-BB41-C8434F6B3C7FQ33870879-CDA26C01-AC37-473F-99FE-43C4AC6EAC18Q33956262-4F527DA7-E8C7-482B-AC57-43522D02AE9DQ34424982-B833A10C-82FF-4B66-B205-69E90FAA6A93Q34684387-B1D79E4E-9989-4FF3-A943-DCFB99485BD3Q34728904-078B9293-123B-4374-B461-3339D8E3B5D8Q35031696-A8D094B3-708B-4CBD-B7D8-1C883A332C54Q35187053-E27656C5-095F-41E0-99A4-628AEAE7F5A6Q35846757-811B539F-78F8-4938-A1CE-84418CC57403Q35985186-2A38F672-0F00-4136-B19B-50D661EA9BC4Q36122563-9CF26CC2-649A-49E2-901F-236AE2CD39E3Q37237829-81F56A70-F92E-4BBF-A7AD-9736F5E07434Q37990399-ABDC6CE5-CE01-409D-9382-1B59A7FB3586Q39017820-38DF95F7-179F-4289-AD3C-E574552D9615Q39066397-C2F84975-4497-4C7A-A99D-51FB1C4C2B8AQ39571686-140E84CC-3B72-4B20-9327-D1D83C48BA2CQ40098290-1B7DDDFD-DF4F-4182-9648-567C4C8EBBF1
P2860
Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of the pharmacokine ...... oup using the 111In-DOTA-X-BBN
@nl
Evaluation of the pharmacokine ...... gm in a prostate cancer model.
@en
type
label
Evaluation of the pharmacokine ...... oup using the 111In-DOTA-X-BBN
@nl
Evaluation of the pharmacokine ...... gm in a prostate cancer model.
@en
prefLabel
Evaluation of the pharmacokine ...... oup using the 111In-DOTA-X-BBN
@nl
Evaluation of the pharmacokine ...... gm in a prostate cancer model.
@en
P2093
P2860
P356
P1476
Evaluation of the pharmacokine ...... gm in a prostate cancer model.
@en
P2093
Gary L Sieckman
Jered C Garrison
Said Daibes Figueroa
Samantha V Sublett
Tammy L Rold
Timothy J Hoffman
Wynn A Volkert
P2860
P304
P356
10.1021/BC8001375
P577
2008-08-20T00:00:00Z